Navigation Links
Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects
Date:8/6/2009

NEW YORK, Aug. 6 /PRNewswire/ -- Lumixyl(TM) a non-toxic, non-irritating, synthetic peptide technology shown to significantly help improve the appearance of unwanted discoloration, age spots, sun spots and uneven skin tone is now available through select physicians to help their patients achieve picture perfect skin. A hydroquinone alternative, this new cosmeceutical skin brightening cream can be found in leading physician offices for $120 per 1 ounce pump.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/lumixyl/39490/

(Photo: http://www.newscom.com/cgi-bin/prnh/20090806/NY57783 )

Developed by dermatological researchers at Stanford University, Lumixyl's ground-breaking technology is the only peptide shown to measurably promote healthy skin function in restraining tyrosinase, the enzyme responsible for initiating the overproduction of melanin, that can cause uneven pigmentation and dark spots.

Lumixyl is created for patients seeking more even skin-tone including those with:

  • Melasma
  • Post-inflammatory hyperpigmentation
  • Sun spots, age spots or liver spots
  • Photodamage
  • Hyperpigmentation caused by systemic disease or prescription drugs

Clinical studies demonstrate that topical use of Lumixyl visibly improves mild to moderate hyperpigmentation with excellent volunteer satisfaction in as little as 8 weeks. Studies show that Lumixyl, a chain of ten amino acids, promoted the moderation of melanin more efficaciously than hydroquinone. At equal concentrations, skin that was treated with the Lumixyl peptide expressed a reduced production of melanin by as much as 40 percent compared to those treated with hydroquinone, which reduced production by only 7 percent in the study.

"The results of studies conducted at Stanford are impressive, showing a 40 percent improvement in melanin related darkening.," commented Nowell Solish, MD, FRCP, Assistant Professor at The University of Toronto, co-director of the Non-Melanoma Skin Cancer clinic at Women's College. "When used as directed, Lumixyl appears to significantly help the skin's ability to diminish dark spots imparting users with brighter, more even skin tone while limiting irritation, red blotches or even sensitivity to sunlight."

Moreover, in-use and Repeated Insult Patch Testing (RIPT) studies confirm that Lumixyl is safe for topical use and does not elicit irritation or allergic reaction. It does not cause increased sensitivity to sunlight as do many commonly used brightening agents and is gentle for all skin types and tones.

"Hydroquinone has had some controversy in the recent past and this product offers a non-hydroquinone alternative that shows good clinical efficacy in treating discoloration without causing irritation," stated Neil Sadick, MD, FAAD, FAACS, FACP, FACPh.

Lumixyl Topical Brightening Creme can be used alone or if directed by a physician, to compliment other treatments such as Tretinoin, laser resurfacing and SilkPeel(TM), respectively, to diminish dark spots, uneven pigmentation and improve overall skin tone.

Visible Results without Risk

The RIPT results show that, unlike many alternative lightening ingredients, this peptide does not cause irritation or allergic reactions. Lumixyl is formulated to provide the following key advantages:

  • Non-toxic
  • Non-irritating
  • Water-soluble
  • Safe for all skin types
  • Produces no harmful by-products
  • Has no cytotoxic effect

Lumixyl products are made exclusively for dermatologists, plastic surgeons and skin oriented aesthetic physicians. The products are co-marketed in the United States by Basis Medical Technologies and Envy Medical.

ABOUT BASIS -- BASIS Medical Technologies specializes in the development and distribution of groundbreaking technologies in medicine and medical aesthetics. Headquartered in Toronto, Canada, BASIS is an innovative technology platform with sales, marketing and training capabilities around the world. With an experienced management team and medical advisory panel, BASIS is committed to delivering and developing cutting-edge medical products internationally. Basis is an exclusive market representative for Lumixyl, a product licensed by Envy Medical Inc..

ABOUT ENVY MEDICAL -- Envy Medical, working through its commercial subsidiary, E Med Inc., develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company's lead products include SilkPeel(R), a breakthrough device combining exfoliation with dermalinfusion(R) for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.4emed.com.

For more information on Lumixyl or to locate a dispensing physician near you, please contact: info@basismedtech.com.


'/>"/>
SOURCE BASIS Medical Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning
2. Photos: Americas Chronically Ill Children Have New Hope with Hot Gift
3. Photos: Drink Wine and Live Longer - 1907 Madiran and Plaimont Wines of Southwest France Sponsor the Launch of The Red Wine Diet
4. Photos: Niavin Corporation Offers Pain Sufferers a New Way to Address Pain
5. Photos: Compact Barbell System With Flat, Streamlined Profile Travels Easily and Stores Conveniently
6. Photos: New Smoking Prevention Program Launched in Schools
7. Photos: New Kind of Health Care Reform Brings Five-Star Hospitality to Hospital Care
8. Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger
9. Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs
10. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
11. Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alexs Lemonade Stand Foundation Join facebook(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 , ... Support of value-based ... simplify the secure exchange of data across industry solutions, Fogo Data Centers announces the ... of community. A healthy community is one in which all systems work well, ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... of the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ ... is backed by giants including Accenture, GE Ventures, and Software AG , ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... protein espresso drinks, announced its products are now available for purchase on RonnieColemanNutrition.com, ... Drink Mix has become popular among health-conscious consumers who love coffee but are ...
(Date:2/20/2017)... ... ... Nancy Johnston Toll marks her debut in the publishing scene ... in the Road ” (published by Xlibris). Inspired from her personal experiences, this compendium ... and downs experienced by anyone going through cancer treatment and how one can be ...
(Date:2/20/2017)... ... February 20, 2017 , ... For ... Orbita, Inc., a leading provider of innovative software for connected home healthcare, today ... and optimizing care journey management for home healthcare. , Built on ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... BEACH, Va. , Feb. 21, 2017  Global ... now covers Dermacell ® for breast ... foot ulcers. Dermacell is an advanced acellular dermal matrix ... Technologies, Inc. (NASDAQ: NVDQ ) ... the four major commercial health-care payers to review the ...
(Date:2/21/2017)... , Feb. 21, 2017 Sangamo Therapeutics, ... announced today that the company will release its fourth ... market opens on Tuesday, February 28, 2017. The press ... 8:30 a.m. ET, which will be open to the ... the company will review its financial results and provide ...
(Date:2/21/2017)... -- Lexmark International, Inc., ... that connects Lexmark multifunction printers (MFPs) to EDCO Health ... scanning and indexing software solutions for medical records. ... a Lexmark MFP at the point of care to ... reach HIMSS Stage 7 through state-of-the-art technology ...
Breaking Medicine Technology: